Literature DB >> 24474226

Evaluation of N-ratio in selecting patients for adjuvant chemoradiotherapy after d2-gastrectomy.

Wilson Luiz da Costa Junior1, Felipe José Fernández Coimbra1, Thales Paulo Batista2, Héber Salvador de Castro Ribeiro1, Alessandro Landskron Diniz1.   

Abstract

CONTEXT: Whether adjuvant chemoradiotherapy may contribute to improve survival outcomes after D2-gastrectomy remains controversial.
OBJECTIVE: To explore the clinical utility of N-Ratio in selecting gastric cancer patients for adjuvant chemoradiotherapy after D2-gastrectomy.
METHODS: A retrospective cohort study was carried out on gastric cancer patients who underwent D2-gastrectomy alone or D2-gastrectomy plus adjuvant chemoradiotherapy (INT-0116 protocol) at the Hospital A. C. Camargo from September 1998 to December 2008. Statistical analysis were performed using multiple conventional methods, such as c-statistic, adjusted Cox's regression and stratified survival analysis.
RESULTS: Our analysis involved 128 patients. According to c-statistic, the N-Ratio (i.e., as a continuous variable) presented "area under ROC curve" (AUC) of 0.713, while the number of metastatic nodes presented AUC of 0.705. After categorization, the cut-offs provide by Marchet et al. displayed the highest discriminating power - AUC value of 0.702. This N-Ratio categorization was confirmed as an independent predictor of survival using multivariate analyses. There also was a trend of better survival by adding of adjuvant chemoradiotherapy only for patients with milder degrees of lymphatic spread - 5-year survival of 23.1% vs 66.9%, respectively (HR = 0.426, 95% CI 0.150-1.202; P = 0.092).
CONCLUSIONS: This study confirms the N-Ratio as a tool to improve the lymph node metastasis staging in gastric cancer and suggests the cut-offs provided by Marchet et al. as the best way for its categorization after a D2-gastrectomy. In these settings, the N-Ratio appears a useful tool to select patients for adjuvant chemoradiotherapy, and the benefit of adding this type of adjuvancy to D2-gastrectomy is suggested to be limited to patients with milder degrees of lymphatic spread (i.e., NR2, 10%-25%).

Entities:  

Mesh:

Year:  2013        PMID: 24474226     DOI: 10.1590/S0004-28032013000400004

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  3 in total

1.  Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.

Authors:  Yuhree Kim; Malcolm H Squires; George A Poultsides; Ryan C Fields; Sharon M Weber; Konstantinos I Votanopoulos; David A Kooby; David J Worhunsky; Linda X Jin; William G Hawkins; Alexandra W Acher; Clifford S Cho; Neil Saunders; Edward A Levine; Carl R Schmidt; Shishir K Maithel; Timothy M Pawlik
Journal:  Surgery       Date:  2017-05-31       Impact factor: 3.982

2.  Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer.

Authors:  Brice Jabo; Matthew J Selleck; John W Morgan; Sharon S Lum; Khaled Bahjri; Mayada Aljehani; Carlos A Garberoglio; Mark E Reeves; Jukes P Namm; Naveenraj L Solomon; Fabrizio Luca; Gary Yang; Maheswari Senthil
Journal:  J Gastrointest Oncol       Date:  2018-08

3.  The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial.

Authors:  Youjin Kim; Se Hoon Park; Kyoung-Mee Kim; Min Gew Choi; Jun Ho Lee; Tae Sung Sohn; Jae Moon Bae; Sung Kim; Su Jin Lee; Seung Tae Kim; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang
Journal:  J Gastric Cancer       Date:  2016-06-24       Impact factor: 3.720

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.